Where Things Stand in 2026
Loyal for Dogs, founded by Celine Halioua, is attempting something unprecedented: bringing the first FDA-approved longevity drug to market for any species. The company is developing two distinct products targeting different dog populations through different biological mechanisms. Understanding the current status requires separating what has been achieved from what remains ahead.
For the foundational overview of Loyal’s program and drug mechanisms, see Loyal’s longevity drug program.
Current status as of May 25, 2026: LOY-002 is not approved or available yet. Loyal has publicly reported FDA acceptance of the Reasonable Expectation of Effectiveness section and the Target Animal Safety section for LOY-002. The remaining major public hurdle is Chemistry, Manufacturing, and Controls (CMC), the manufacturing-quality section required before conditional approval can be granted. For owners who want the practical prescription-readiness version, see LOY-002 for senior dogs: approval status, eligibility, safety, and cost.
LOY-001: For Large and Giant Breed Dogs
What It Does
LOY-001 targets the excess IGF-1 (insulin-like growth factor 1) signaling that drives accelerated aging in large and giant breed dogs. Elevated IGF-1 is mechanistically linked to faster growth, earlier disease onset, and shorter lifespan in large breeds — a relationship documented across multiple species. See IGF-1 and canine lifespan.
The drug is a long-acting injectable designed to reduce IGF-1 levels to a range more consistent with smaller, longer-lived dogs. The goal is not to stop aging but to reduce the metabolic overdrive that makes large dogs age disproportionately fast.
Regulatory Status
LOY-001 is pursuing FDA conditional approval under the MUMS (Minor Use and Minor Species) pathway. The three major FDA requirements for conditional approval are:
- Target Animal Safety (TAS) — demonstrating the drug does not harm dogs at therapeutic and elevated doses.
- Reasonable Expectation of Effectiveness (RXE) — providing evidence that the drug is likely to work as claimed, pending full effectiveness data.
- Chemistry, Manufacturing, and Controls (CMC) — demonstrating consistent, quality-controlled drug production.
Loyal has not publicly disclosed the status of all three components for LOY-001 as of early 2026. The drug targets a specific population (large/giant breeds) and a novel indication (longevity), which creates both regulatory opportunity (MUMS pathway flexibility) and challenge (no precedent for longevity claims).
Target Population
LOY-001 would be prescribed for healthy large and giant breed dogs in early to mid-adulthood — breeds like Great Danes, Irish Wolfhounds, Bernese Mountain Dogs, Newfoundlands, Saint Bernards, and Mastiffs whose lifespans are typically 6-10 years.
Loyal’s current product materials also describe LOY-003 as a daily-pill large/giant-dog program targeting the same broad size-lifespan biology. That matters for internal planning because large-breed owners may search for “LOY-001,” “LOY-003,” “large dog longevity drug,” or breed-specific versions such as “Great Dane longevity drug.” Puppy Longevity should keep this hub as the comparison page and link breed guides back here for drug-program context.
LOY-002: For Senior Dogs
What It Does
LOY-002 targets metabolic dysfunction in senior dogs aged 10 and older. Rather than addressing a single pathway like IGF-1, LOY-002 aims to improve metabolic health parameters that decline with aging — essentially addressing the biological deterioration that accelerates in old age.
The specific mechanism has not been fully disclosed publicly, but Loyal has described it as addressing age-related metabolic decline that contributes to frailty, disease susceptibility, and quality-of-life deterioration in senior dogs. Age-related conditions such as arthritis, cancer, cognitive decline, and heart disease are among the practical owner concerns surrounding this metabolic approach.
Loyal’s veterinary overview describes LOY-002 as intended for dogs 10 years or older and weighing at least 14 lb. The final FDA label, if approval is granted, should be treated as the source of truth for eligibility, monitoring, contraindications, and allowed claims.
Regulatory Status
LOY-002 has achieved the most regulatory progress:
- January 2026: FDA accepted the Target Animal Safety (TAS) section, confirming the drug’s safety profile meets regulatory requirements.
- February 2025: FDA accepted the Reasonable Expectation of Effectiveness (RXE), confirming that Loyal’s evidence for likely effectiveness meets the threshold for conditional approval.
With TAS and RXE completed, LOY-002 has satisfied 2 of the 3 major requirements for conditional approval. The remaining requirement is Chemistry, Manufacturing, and Controls (CMC).
Owners searching for availability should be clear on the practical implication: LOY-002 is still not something a veterinarian can prescribe today. Conditional approval would be the point at which qualified veterinarians could prescribe the drug to label-matched dogs while full effectiveness data continues to mature.
The STAY Trial
Loyal’s STAY clinical trial enrolled approximately 1,300 senior dogs across multiple veterinary sites — making it the largest veterinary clinical trial in history. The trial assesses whether LOY-002 extends healthy lifespan in senior dogs by tracking survival, disease events, quality of life, and biomarker trajectories.
STAY data contributed to the RXE acceptance, meaning the FDA found the preliminary evidence sufficient to establish a reasonable expectation that the drug works. However, conditional approval requires continued post-market data collection to confirm full effectiveness.
Timeline: What Is Realistic
Regulatory timelines are inherently uncertain, but based on current progress:
LOY-002 is closest to market. With TAS and RXE accepted, conditional approval depends on completing the CMC submission and FDA review. If CMC review proceeds without significant issues, conditional approval could occur as early as late 2026 or 2027. Post-conditional-approval, the drug would be available by prescription through veterinarians while Loyal continues collecting effectiveness data for full approval.
LOY-001 is earlier in the regulatory process. A realistic timeline for conditional approval is 2027-2028, depending on the status of its regulatory submissions.
These estimates assume no significant regulatory setbacks, manufacturing delays, or safety signals. Drug development timelines frequently shift.
What Conditional Approval Means
FDA conditional approval is not the same as full approval:
- The drug is available for sale by prescription.
- The manufacturer must continue collecting effectiveness data and submit annual reports.
- Conditional approval is renewed annually for up to 5 years, during which full effectiveness data must be provided.
- If full effectiveness is not demonstrated within the conditional approval period, the drug is removed from market.
This pathway allows promising drugs to reach patients while effectiveness data is still being collected — a meaningful advantage for longevity drugs where definitive lifespan data requires years of observation.
What This Means for Dog Owners
What to do now
- Do not wait for Loyal drugs to address your dog’s health. Every evidence-based longevity intervention available today — lean body condition, exercise, preventive care, dental health — should be pursued independently of pharmaceutical development.
- Be cautious of off-label longevity drugs. Some owners seek rapamycin, metformin, or other compounds through veterinarians willing to prescribe off-label. These drugs have different evidence profiles and risk considerations. See rapamycin in dogs and metformin for dogs.
- Maintain realistic expectations. Even if approved, Loyal’s drugs are unlikely to double a dog’s lifespan. The goal is meaningful extension of healthy years — perhaps 1-3 additional years of quality life. That is significant, but it is not a miracle.
If your dog is in the target population
- Large/giant breed owners: keep your dog healthy and at ideal body weight so they are good candidates when LOY-001 becomes available.
- Senior dog owners: maintain comprehensive veterinary care, cognitive decline monitoring, and quality-of-life assessment. See canine frailty signals and the dedicated LOY-002 senior dog guide.
The Broader Significance
If Loyal achieves FDA approval for either drug, it will be the first time a regulatory agency has approved a drug specifically to extend lifespan in any species. This precedent has implications beyond veterinary medicine — it could influence regulatory frameworks for human longevity drugs and validate the concept of aging as a targetable condition rather than an inevitable decline.
Creevy et al. (2025) and Kaeberlein (2016) have both emphasized the translational potential of canine longevity research: dogs share our environments, develop similar age-related diseases, and age on a timescale (10-15 years) that makes clinical trials feasible within a researcher’s career.
Limitations
Loyal is a venture-backed company with over $150M in funding and significant commercial incentives to present its progress favorably. Regulatory milestone announcements are positive signals but do not guarantee approval. Full effectiveness data is not yet available for either drug. Pricing, insurance coverage, and practical accessibility remain unknown. The longevity extension magnitude (how many additional healthy years the drugs provide) will not be fully characterized until post-approval data collection is complete.
Frequently Asked Questions
When will Loyal’s longevity drugs be available for my dog?
LOY-002, which targets metabolic dysfunction in senior dogs, has completed 2 of 3 FDA requirements for conditional approval. If the remaining manufacturing submission proceeds without setbacks, conditional approval could occur as early as late 2026 or 2027. LOY-001 and LOY-003 for large and giant breeds are earlier in the regulatory process.
Is LOY-002 available from veterinarians now?
No. LOY-002 is not approved or available as of May 25, 2026. A veterinarian cannot prescribe it until FDA grants approval and Loyal launches it through veterinary channels.
Which dogs might be eligible for LOY-002?
Loyal describes LOY-002 as intended for senior dogs age 10 or older and at least 14 lb. The final label should be treated as the decision standard once the product is approved.
How much longer could these drugs help my dog live?
Loyal has not disclosed specific lifespan extension data from its clinical trials. The realistic expectation is meaningful extension of healthy years — perhaps 1-3 additional years of quality life — rather than a dramatic lifespan doubling. The exact magnitude of benefit will not be fully characterized until post-approval data collection is complete.
What should I do for my dog’s longevity while waiting for Loyal’s drugs?
Every evidence-based longevity intervention available today should be pursued independently of pharmaceutical development. Maintaining lean body condition, providing regular exercise, ensuring dental health, following appropriate preventive care schedules, and managing any chronic conditions are all proven to extend healthy lifespan and should not wait for drug availability.
Will Loyal’s drugs be expensive?
Pricing has not been announced. As prescription veterinary pharmaceuticals, they will likely be available through veterinarians. Given the $150M+ venture funding behind development, pricing will need to balance accessibility with commercial viability. Insurance coverage and practical accessibility remain unknown.
Bottom Line
Loyal for Dogs has made significant regulatory progress, with LOY-002 (for senior dogs) completing 2 of 3 FDA requirements for conditional approval and LOY-001 (for large/giant breeds) advancing through the regulatory process. If approved, these would be the first FDA-approved longevity drugs for any species. Realistic timelines suggest LOY-002 could reach the market in late 2026 or 2027, with LOY-001 following in 2027-2028. Owners should pursue all available evidence-based longevity interventions now rather than waiting for pharmaceutical solutions, while maintaining realistic expectations about what these drugs can achieve.